Diagnostic Specialty Antibodies Market Size

Diagnostic Specialty Antibodies Market Analysis

The diagnostic specialty antibodies market is projected to grow with a CAGR of 5.95%, during the forecast period. 

The COVID-19 pandemic has had a substantial impact on the diagnostic specialty antibodies market. The usage of diagnostic antibodies underwent a significant rise during the pandemic as these antibodies were adopted quickly for the detection of COVID-19 during the pandemic. For instance, according to an article published by PubMed Central in February 2021, the main-stream diagnostic methods used during the pandemic to detect the presence of SARS-CoV-2 virus in the laboratory include nucleic acid PCR tests and direct viral antigen tests for detecting active infections, and indirect human antibody tests specific to SARS-CoV-2 to detect prior exposure. Furthermore, according to FDA in February 2022, SARS-CoV-2 antibody tests can help identify people who may have been infected with the SARS-CoV-2 virus or have recovered from COVID-19. But the antibody tests cannot be used to detect active COVID-19 infection. Currently, the usage of antibodies for COVID-19 testing lowered drastically as other tests like PCR and antigen tests have become much more popular due to the confirmatory results that they provide. Thus, the COVID-19 outbreak affected the market's growth favorably in its preliminary phase; however, during the forecast period, the market is likely to go back to how it was during the pre-pandemic phase.

The advancements in DNA-based technologies and diagnostics are expected to boost market growth. In addition, the high number of patient pools undergoing diagnosis of HIV and the growing demand for specialty diagnostics around the world are projected to fuel the market. Furthermore, the increase in the prevalence of diseases such as infectious diseases, influenza, and cancer is expected to boost the diagnostic antibodies market.

For instance, according to an article published by BMC in January 2022, immunohistochemistry (IHC) using monoclonal and polyclonal antibodies is a very useful and popular diagnostic method for detecting pathogen antigens in fixed tissues, it complements the direct diagnosis of infectious diseases by PCR and culture on fresh tissues. The article also stated that the immunohistochemical technique is a rapid and efficient way of identifying HIV antigens in fixed surgical and autopsy specimens. The immunohistochemistry technique using an anti-p24 monoclonal antibody has proven to be very useful for detecting HIV in lymph node biopsies of patients with unexplained follicular hyperplasia.

In addition, new key developments and strategic activities by major players in the market are positively affecting the growth of the studied market. For example, according to an article published by MDPI in April 2021, monoclonal antibodies are an emerging tool for cancer diagnosis, treatment and even delivering radiation or chemotherapy to targeted areas of the body. Recently, researchers have cloned a new anti-p16 antibody that may become a new valuable tool for pathological cancer diagnosis. Thus, owing to the product launches and partnerships, the studied market is expected to have significant growth over the forecast period.

However, the high cost of the development of antibodies in rapid diagnosis is expected to hamper the market growth.